{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-dateTabled=2018-11-21&hansardHeading=Medical+Treatments%3A+Innovation", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-dateTabled=2018-11-21&hansardHeading=Medical+Treatments%3A+Innovation", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-dateTabled=2018-11-21&_metadata=all&hansardHeading=Medical+Treatments%3A+Innovation", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-dateTabled=2018-11-21&hansardHeading=Medical+Treatments%3A+Innovation", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-dateTabled=2018-11-21&hansardHeading=Medical+Treatments%3A+Innovation", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-dateTabled=2018-11-21&hansardHeading=Medical+Treatments%3A+Innovation", "items" : [{"_about" : "http://data.parliament.uk/resources/994211", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/994211/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) it has recently set up a commercial function that specifically focuses on engaging in discussions around commercial arrangements - The Commercial and Managed Access Programme. Through this function, NICE will provide companies with opportunities to engage in commercial and managed access conversations with both NICE and NHS England.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-01", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-01T16:46:48.487Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-24", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans the National Institute for Health and Care Excellence has to facilitate commercial discussions between manufacturers and NHS England at an early stage in its evaluations of highly specialised technologies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4661", "label" : {"_value" : "Biography information for Jared O'Mara"}
      }
      , "tablingMemberConstituency" : {"_value" : "Sheffield, Hallam"}
      , "tablingMemberPrinted" : [{"_value" : "Jared O'Mara"}
      ], "uin" : "183457"}
    , {"_about" : "http://data.parliament.uk/resources/992642", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/992642/answer", "answerText" : {"_value" : "<p>To date, the National Institute for Health and Care Excellence (NICE) has recommended all eight medicines that it has evaluated through its highly specialised technologies (HST) programme for some or all of the eligible patient population, in most cases subject to managed access agreements that specify clinical criteria and data collection requirements. National Health Service organisations are legally required to fund medicines recommended in NICE\u2019s HST guidance, and patients with the rare diseases concerned are now benefitting from access to the medicines in line with NICE\u2019s recommendations.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-10-30", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "182200"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-30T15:52:26.857Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-22", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the (a) criteria used for and (b) long term data collection requirement of the highly specialised technologies process.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "182202"}
    , {"_about" : "http://data.parliament.uk/resources/964649", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/964649/answer", "answerText" : {"_value" : "<p>The Accelerated Access Collaborative (AAC) has been successfully established, meeting for the first time in January 2018 and agreeing terms of reference and ways of working. Lord Darzi is the new chair of the AAC, replacing Sir Andrew Witty, who stood down to avoid any conflict of interest with his new role as CEO of Optum. We expect that the Accelerated Access Pathway will launch at the next meeting of the AAC, which will be in the autumn.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-09-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-09-11T14:37:19.627Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-09-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress his Department has made on establishing an Accelerated Access Collaborative to manage the new accelerated access pathway.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"}
      }
      , "tablingMemberConstituency" : {"_value" : "Stafford"}
      , "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"}
      ], "uin" : "169360"}
    , {"_about" : "http://data.parliament.uk/resources/964650", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/964650/answer", "answerText" : {"_value" : "<p>The Accelerated Access Collaborative will meet this autumn to launch the Accelerated Access Pathway and the first group of products will be part of their discussions.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-09-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-09-11T14:35:39.31Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-09-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, when the accelerated access pathway is planned to begin designating breakthrough products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"}
      }
      , "tablingMemberConstituency" : {"_value" : "Stafford"}
      , "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"}
      ], "uin" : "169361"}
    , {"_about" : "http://data.parliament.uk/resources/964651", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/964651/answer", "answerText" : {"_value" : "<p>The establishment of the pathway has been led by the Accelerated Access Collaborative (AAC), working with industry and patients. The establishment of the AAC has been supported by the Office for Life Sciences, which is a joint unit between both the Department for Business, Energy and Industrial Strategy (BEIS) and the Department of Health and Social Care (DHSC). A member of the BEIS departmental board sits on the AAC.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3980", "label" : {"_value" : "Biography information for Mr Sam Gyimah"}
        }
        , "answeringMemberConstituency" : {"_value" : "East Surrey"}
        , "answeringMemberPrinted" : {"_value" : "Mr Sam Gyimah"}
        , "dateOfAnswer" : {"_value" : "2018-09-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-09-11T14:24:44.973Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2018-09-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what involvement his Department has had in the establishment of the new accelerated access pathway.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"}
      }
      , "tablingMemberConstituency" : {"_value" : "Stafford"}
      , "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"}
      ], "uin" : "169362"}
    , {"_about" : "http://data.parliament.uk/resources/937431", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/937431/answer", "answerText" : {"_value" : "<p>In December 2017, the Government published the Life Sciences Sector Deal, which detailed our commitments to taking forward the ambition in the Life Sciences Industrial Strategy. This included implementing the response to the Accelerated Access Review, which sets out a plan to increase the rate of uptake of innovative products.<\/p><p> <\/p><p>In delivering this response, the Government has brought together the key Government, National Health Service and industry partners to form the Accelerated Access Collaborative (AAC) which will drive the uptake and adoption of innovation in the NHS, identifying and supporting the innovations that will be most transformative for patients.<\/p><p> <\/p><p>The AAC will oversee the Accelerated Access Pathway, streamlining regulatory and market access decisions, and providing additional support to increase uptake of the most transformative innovations.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-07-17", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-07-17T11:34:46.727Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-07-09", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what his policy priorities are in the Accelerated Access Pathway programme; and what the implications are of that programme for life-extending treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leeds North West"}
      , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
      ], "uin" : "162145"}
    , {"_about" : "http://data.parliament.uk/resources/917333", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/917333/answer", "answerText" : {"_value" : "<p>We are currently in the process of appointing a new chair for the Accelerated Access Collaborative (AAC). Following this appointment, the AAC will meet to launch the Accelerated Access Pathway and will consider the first group of products as part of their discussions.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-06-13", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-06-13T15:22:22.517Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether the products for the accelerated access pathway have now been selected; and when an announcement on such products is planned.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "150123"}
    , {"_about" : "http://data.parliament.uk/resources/906390", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/906390/answer", "answerText" : {"_value" : "<p>The Accelerated Access Collaborative will meet shortly to launch the Accelerated Access Pathway, and will consider the first group of products as part of their discussions.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-23T15:32:51.013Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-17", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the timetable is for the announcement of the treatments selected for the accelerated access pathway.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
      }
      , "tablingMemberConstituency" : {"_value" : "Strangford"}
      , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
      ], "uin" : "145338"}
    , {"_about" : "http://data.parliament.uk/resources/904023", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/904023/answer", "answerText" : {"_value" : "<p>The Life Sciences Industrial Strategy set out our vision of being a world-leader in developing and bringing to market innovative medicines to improve patient outcomes. It highlighted the importance of evolving and simplifying the access system for new medicines by implementing, and building on, the findings of the Accelerated Access Review.<\/p><p> <\/p><p>The response to the Accelerated Access Review, published last year, set out a series of actions the Government and the National Health Service are taking to increase the rate of uptake of innovative products. We have brought together the key Government, NHS and industry partners together through the newly formed Accelerated Access Collaborative, who will oversee the Accelerated Access Pathway, to streamline regulatory and market access decisions, getting breakthrough products that we believe will be truly transformative to patients more quickly. The response also committed to £86 million of support, including £39 million to improve local adoption and uptake of innovative medical technologies through a greater role for the Academic Health and Science Networks and £6 million to help the NHS to adopt and integrate new technologies into everyday practice, through the Pathway Transformation Fund. These build on our existing schemes to encourage quicker patient access such as the Early Access to Medicines Scheme and the Innovation Technology Tariff. Additionally, the Innovation Scorecard tracks the uptake of cost-effective new medicines approved by the National Institute for Health and Care Excellence.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-22T14:12:45.53Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-14", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to shorten the approval process time for treatments that are not selected for the accelerated access pathway.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leeds North West"}
      , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
      ], "uin" : "143872"}
    , {"_about" : "http://data.parliament.uk/resources/900158", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/900158/answer", "answerText" : {"_value" : "<p>The Life Sciences Industrial Strategy set out our vision of being a world-leader in developing and bringing to market innovative medicines to improve patient outcomes. It highlighted the importance of evolving and simplifying the access system for new medicines by implementing, and building on, the findings of the Accelerated Access Review. The Early Access to Medicines Scheme (EAMS) is an important part of delivering on this ambition.<\/p><p> <\/p><p>The Department works closely with NHS England to make a success of EAMS, jointly attending a task group with industry, the devolved administrations and arms length bodies to drive improvements to the scheme. NHS England is involved throughout the EAMS process, receiving advance notice before a product receives a positive Scientific Opinion. This enables NHS England to carry out earlier engagement with industry to prepare to provide access to the drug during the EAMS period.<\/p><p> <\/p><p>Access to drugs through EAMS will not be universal, however as it is for individual clinicians to determine whether they believe it is right to offer the medicine to patients. We believe this is the right approach because EAMS products are unlicensed medicines. For a drug that applies to specialised commissioning, access will only be allowed in those centres who meet the appropriate service specification.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-16", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-16T11:32:30.383Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Innovation"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on ensuring equitable access to treatments following a positive scientific opinion through the Early Access to Medicines Scheme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4532", "label" : {"_value" : "Biography information for Derek Thomas"}
      }
      , "tablingMemberConstituency" : {"_value" : "St Ives"}
      , "tablingMemberPrinted" : [{"_value" : "Derek Thomas"}
      ], "uin" : "141865"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-dateTabled=2018-11-21&hansardHeading=Medical+Treatments%3A+Innovation", "page" : 0, "startIndex" : 1, "totalResults" : 71, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}